Business · 26/02/1997Updated: 10/17/2026 · 1 min read
FDA Announces Meeting of Oversight Committee to Review Refusal to File Practices
Summary
The FDA is holding a meeting of its oversight committee to review the agency's use of refusal to file practices on product, establishment, and biologics license applications, with a focus on consistency across CBER offices and divisions.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →